Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14994067 | 1.00 | RIPK1 (0.33) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL16246924 | 1.00 | RIPK1 (0.33) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL344649 | 1.00 | RIPK1 (0.33) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL860060 | 1.00 | RIPK1 (0.33) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL771956 | 0.90 | POLB (0.41) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL5469615 | 0.90 | POLB (0.41) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL506328 | 0.90 | RIPK1 (0.31) | RIPK1POLBL3MBTL1 | |
| SCHEMBL1975621 | 0.90 | POLB (0.41) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL8646401 | 0.90 | POLB (0.41) | RIPK1POLBL3MBTL1LMNACYP2C19 | |
| SCHEMBL6398284 | 0.86 | RIPK1 (0.31) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-06-29 | — | — | US | disclosed |
| CN-107849019-A | A kind of azepine Cydic amide derivatives and preparation method thereof and purposes in medicine | 四川海思科制药有限公司 | 2018-03-27 | — | — | CN | disclosed |
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ABL1, EGFR | RIPK1 1813/4885POLB 1188/4885L3MBTL1 3582/4885 |
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | RIPK1 745/4885POLB 25/4885L3MBTL1 3291/4885 |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | RIPK1 489/4885POLB 78/4885L3MBTL1 3158/4885 |
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | RIPK1 3797/4885POLB 2575/4885L3MBTL1 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.